 Zacks Investment Research downgraded shares of LogicBio Therapeutics NASDAQ:LOGC from a hold rating to a sell rating in a research note released on Thursday morning, Zacks.com reports. According to Zacks, LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The ... 